



MARKET RELEASE

3 November 2016

Neurotech International Limited

PRE-QUOTATION DISCLOSURE

Neurotech International Limited (the “Company”) was admitted to the Official List of ASX Limited on Thursday 3 November 2016.

Official Quotation of the Company’s securities will commence at 1pm AEDT (10am WST) on Friday 4 November 2016.

The following information is released as pre-quotation disclosure.

1. Appendix 1A and Information Form and Checklist.
2. Distribution schedule.
3. Top 20 holders.
4. Prospectus
5. Constitution.
6. The Company’s audited accounts for the full year ended 30 June 2016 and AAT Research Limited’s audited accounts for the full years ended 31 December 2013, 31 December 2014 and 30 December 2015.
7. Securities Trading Policy.
8. A statement setting out the number of securities subject to ASX restrictions and the restriction period applied to those securities.
9. The full terms and conditions of all options on issue.
10. A statement providing the following:



- 10.1. An update on the status of the preparation of formal documentation codifying the manufacturing agreement between AAT Medical Limited and MCL Components Limited;
- 10.2. The agreement dated 7 September 2016 between the Company and Adrian Attard Trevisan to replace the AAT Research Limited options with 130,480 Company options has been amended to issue Adrian Attard Trevisan with 1,864,000 options as stipulated on page 127 of the Prospectus;
- 10.3. An update on the status of the following distributor agreements between AAT Medical Limited and various distributors which have expired or are due to expire:
 - 10.3.1. Pureline Medical Co. in Saudi Arabia;
 - 10.3.2. Pureline Medical Co in Bahrain, Oman, Qatar, Kuwait, Jordan and United Arab Emirates;
 - 10.3.3. A company bearing registration number S-9605 in Iraq;
 - 10.3.4. MHT-Group SARL in Lebanon.
- 10.4. An update on the status of the patent protecting the technology for providing treatment using Cranial Electrotherapy Stimulation (CES) being application PAT/4364 on 23 April 2015 applied by AAT Research Limited and AAT Intellectual Property Limited;
- 10.5. An update as to the current amount outstanding under the banking facilities provided by the Bank of Valletta to AAT Medical Limited and AAT Research Limited; and
- 10.6. A statement confirming that the amount of \$2,104,000 committed to “Sales and marketing for Mente Autism” as stipulated on page 16 of the Prospectus, is not conditional on the successful outcome of the clinical trials currently being conducted in the United States of America as detailed in sections 3.4 and 7.2(h) of the Prospectus.

Security Code: NTI

Anjuli Sinniah
Adviser, Listings Compliance (Perth)